社区医院环境下颈动脉内膜剥脱术、经股动脉颈动脉支架术与经颈动脉血运重建术的比较结局:多中心回顾性研究
该多中心回顾性研究纳入2016至2023年HCA医疗系统37,482例症状性颈动脉狭窄患者,比较CEA、TCAR与TF-CAS的围术期及1年结局。结果显示CEA与TCAR围术期安全性相似,TF-CAS的90天卒中及30天死亡率更高,1年再狭窄率三组均低且无显著差异。
要点
- 症状性患者中CEA与TCAR围术期安全性相当,均可作为安全有效的选择。
- TF-CAS与更高的90天卒中和30天死亡率相关,需根据解剖及患者因素选择性使用。
- 三种术式1年再狭窄率均低且调整后无显著差异。
核心结论
- 在症状性颈动脉狭窄患者中,CEA与TCAR围术期安全性相似,TF-CAS与更高的90天卒中和30天死亡率相关。
- 三种术式1年再狭窄率均低且可比,支持CEA和TCAR作为症状性患者的安全有效选择。
研究设计与样本
- 多中心回顾性分析,纳入2016至2023年HCA Healthcare系统37,482例接受CEA、TCAR或TF-CAS的症状性患者。
- 症状性定义为记录的同侧卒中、短暂性脑缺血发作(TIA)或一过性黑矇。
- 采用Firth校正的多变量logistic回归评估术式与结局的关联,调整年龄、Elixhauser合并症指数和抗血小板治疗。
主要发现
- 37,482例中,CEA 28,021例(74.76%),TF-CAS 8,603例(22.95%),TCAR 858例(2.29%)。
- 90天卒中率:TCAR 2.80%,CEA 3.31%,TF-CAS 5.96%(P < 0.0001)。
- 30天死亡率:TCAR 1.05%,CEA 1.07%,TF-CAS 3.16%(P < 0.0001)。
- 30天伤口感染:TCAR 0/858(0%),CEA 129/28,021(0.46%),TF-CAS 10/8,603(0.12%)(P < 0.0001)。
- 1年再狭窄率:TCAR 1.28%,CEA 0.85%,TF-CAS 0.94%,调整后组间无显著差异(P = 0.35)。
关键数值与推荐
- 90天卒中率TCAR 2.80%、CEA 3.31%、TF-CAS 5.96%(P < 0.0001)。
- 30天死亡率TCAR 1.05%、CEA 1.07%、TF-CAS 3.16%(P < 0.0001)。
- 30天伤口感染TCAR 0/858、CEA 129/28,021(0.46%)、TF-CAS 10/8,603(0.12%)(P < 0.0001)。
- 1年再狭窄率TCAR 1.28%、CEA 0.85%、TF-CAS 0.94%(调整后P = 0.35)。
- 心肌梗死率在各术式间无显著差异。
临床怎么用
- 症状性颈动脉狭窄患者可优先考虑CEA或TCAR,二者围术期安全性相当。
- TF-CAS应基于解剖和患者特异性因素选择性使用,因其卒中及死亡风险较高。
- 术后1年再狭窄率整体较低,但仍需规范随访。
局限性
- 回顾性研究设计可能存在选择偏倚和未测量混杂。
- TCAR组样本量较小(858例),可能影响组间比较的效能。
- 仅调整年龄、Elixhauser合并症指数和抗血小板治疗,未涵盖所有潜在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To compare perioperative and 1-year outcomes of carotid endarterectomy (CEA), transcarotid artery revascularization (TCAR), and transfemoral carotid artery stenting (TF-CAS) using data from a large multicenter real-world cohort of symptomatic patients treated across community hospital settings. METHODS: A retrospective analysis was performed on 37,482 symptomatic patients who underwent CEA, TCAR, or TF-CAS within the HCA Healthcare system from 2016 to 2023. Symptomatic status was defined by documented ipsilateral stroke, transient ischemic attack (TIA), or amaurosis fugax. Primary outcomes included 90-day stroke, 30-day all-cause mortality, 30-day myocardial infarction (MI), 30-day wound infection, and 1-year restenosis. Multivariable logistic regression with firth correction was used to assess associations between procedure type and outcomes, adjusting for age, Elixhauser comorbidity index, and antiplatelet therapy. RESULTS: Of the 37,482 patients included in the analysis, 28,021 (74.76%) underwent CEA, 8,603 (22.95%) underwent TF-CAS, and 858 (2.29%) underwent TCAR. The 90-day stroke rates were 2.80% after TCAR, 3.31% after CEA, and 5.96% following TF-CAS (P < 0.0001). Thirty-day mortality was 1.05% after TCAR, 1.07% after CEA, and 3.16% after TF-CAS (P < 0.0001). Rates of MI did not significantly differ across procedure types. No 30-day wound infections occurred in the TCAR group (0/858), compared with 129/28,021 (0.46%) after CEA and 10/8,603 (0.12%) after TF-CAS (P < 0.0001). One-year restenosis rates were low across all modalities; 1.28% after TCAR, 0.85% after CEA, and 0.94% after TF-CAS with no significant adjusted differences between groups (P = 0.35). CONCLUSION: In this large symptomatic cohort, CEA and TCAR demonstrated similar perioperative safety, while TF-CAS was associated with higher 90-day stroke and 30-day mortality. One-year restenosis rates were low and comparable across all 3 approaches. These findings demonstrate that CEA and TCAR achieve comparably favorable outcomes with low rates of stroke, mortality, and perioperative complications, supporting both as safe and effective options for symptomatic patients. Conversely, TF-CAS was linked to significantly higher stroke risk, underscoring the need for selective use based on anatomy and patient-specific factors. Overall, the results reinforce a personalized, risk-adjusted approach to carotid revascularization.
引用
- Hanandeh A, Zia Z, Cabrera V, et al. Comparative Outcomes of Carotid Endarterectomy, Transfemoral Carotid Artery Stenting, and Transcarotid Artery Revascularization in Community Hospital Settings: A Multicenter Retrospective Study. Ann Vasc Surg. 2026. PMID: 41933576. doi:10.1016/j.avsg.2026.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。